Tangram Therapeutics Advances TGM-312 Into MASH Patient Cohorts
London, UK, September 3, 2026 Tangram Therapeutics announced that its investigational MASH treatment TGM-312 has progressed into Part B...
Phase 1/2 Trial
Advertisement
Satellite Bio Receives FDA Rare Pediatric Disease Designation for SB-101
NEWTON, Mass., May 4, 2026 Satellite Bio announced that the U.S. Food and Drug Administration (FDA) has granted Rare...
IDEAYA Biosciences Advances IDE892 in MTAP-Deleted Cancers
SOUTH SAN FRANCISCO, Calif., July 27, 2026 IDEAYA Biosciences announced the initiation of Part 2 monotherapy expansion in its...
CAMP4 Therapeutics Receives Australian Clearance for First-in-Human CMP-002 Trial
CAMBRIDGE, Mass., July 27, 2026 CAMP4 Therapeutics announced that it has received regulatory clearance from Australia’s Therapeutic Goods Administration...
Prime Medicine Achieves FDA Milestone for PM577a
CAMBRIDGE, Mass., July 23, 2026 Prime Medicine (Nasdaq: PRME) announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
Sana Reports Long-Term Type 1 Diabetes Data
SEATTLE, July 13, 2026 Sana Biotechnology announced the publication of long-term clinical findings in The New England Journal of...
Opus Genetics Provides BEST1 Phase 1/2 Trial Timeline for OPGx-BEST1 Data
RESEARCH TRIANGLE PARK, N.C., July 9, 2026 Opus Genetics announced an important clinical development update for its Phase 1/2...
FibroBiologics Advances CYWC628 DFU Trial Manufacturing
HOUSTON, July 7, 2026 FibroBiologics, Inc. has announced the successful completion of the third manufacturing batch of its investigational...
Epicrispr Advances Epigenetic Therapy With Promising FSHD Clinical Data
SAN FRANCISCO, Calif., June 26, 2026 Epicrispr Biotechnologies announced encouraging interim Phase 1/2 clinical trial results for EPI-321, its...
Siren Biotechnology Secures $8M CIRM Grant for SRN-101 Trial
SAN FRANCISCO, Calif., June 26, 2026 Siren Biotechnology has been awarded an $8 million non-dilutive CLIN2 grant from the...
Advertisement
